Association of serum cholesterol with Parkinson's disease in a cohort of statin-free individuals

Brain Behav. 2022 Jan;12(1):e2454. doi: 10.1002/brb3.2454. Epub 2021 Dec 11.

Abstract

Introduction: The role of serum cholesterol in the pathogenesis of Parkinson's disease (PD) remains unclear. The objective of this study was to assess the association between serum cholesterol and PD in a cohort of statin-free newly diagnosed PD patients.

Methods: This retrospective study used fasting lipid profiles obtained from 672 consecutive statin-free newly diagnosed PD individuals and 540 controls. These PD individuals were identified from three medical institutions during 2017-2021, and the controls were identified from three physical examination centers during the same time period. Logistic regressions were used to estimate odds ratios (ORs) and 95% confidence intervals (CIs), with adjustment of age, sex, and tobacco use history.

Results: Among 672 PD individuals, 112 were excluded in accordance with the current criteria, leaving 560 PD patients. The multivariate binary logistic regression analysis showed that LDL-C was the only variable contributing to the occurrence of PD (OR 1.39, 95% CI: 1.07-2.31, p < .001) after adjusting for age, sex, and tobacco use history; this association persisted following further adjustment for TC and HDL-C. In the subgroup analysis of the adjusted results of LDL-C after correcting for TC and HDL-C, lower LDL-C was associated with a higher risk of PD.

Conclusion: Among selected populations of statin-free newly diagnosed PD individuals, low LDL-C might be associated with the occurrence of PD.

Keywords: Parkinson's disease; association; low-density lipoprotein statin; serum cholesterol; statin.

MeSH terms

  • Cholesterol, LDL
  • Cohort Studies
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors* / therapeutic use
  • Parkinson Disease* / diagnosis
  • Retrospective Studies
  • Risk Factors

Substances

  • Cholesterol, LDL
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors